ADC Therapeutics SA reported its financial results for the second quarter and first half of 2026, revealing a net loss of $16.6 million for the three months ending June 30, 2026, a significant improvement compared to a net loss of $56.6 million for the same period in 2025. For the first half of 2026, the company recorded a net loss of $49.5 million, down from $95.2 million in the prior year. Total revenue for the second quarter increased to $19.2 million, up 2.2% from $18.8 million in the same quarter last year, driven primarily by a 3.0% increase in product revenues from ZYNLONTA, which reached $18.6 million.
In terms of operational efficiency, ADC Therapeutics has made notable strides, reducing total operating expenses by 29.1% to $44.7 million in the second quarter of 2026, compared to $63.0 million in the same quarter of 2025. This reduction was largely attributed to a significant decrease in research and development expenses, which fell by 42.3% to $17.4 million, reflecting the company's strategic decision to focus resources on ZYNLONTA and discontinue certain preclinical programs. The company also reported a decrease in restructuring costs, which dropped to $2.7 million in the second quarter from $13.1 million in the prior year.
Strategically, ADC Therapeutics is undergoing a reorganization aimed at enhancing its focus on ZYNLONTA, including a planned reduction of approximately 17% of its global workforce. This restructuring is expected to be completed by September 30, 2026, and is part of the company's broader strategy to streamline operations and improve efficiency. The company has also made progress in its clinical trials, with the LOTIS-5 trial achieving statistical significance in its primary endpoint of progression-free survival, and the LOTIS-7 trial completing enrollment.
As of June 30, 2026, ADC Therapeutics reported cash and cash equivalents of $219.1 million, a decrease from $261.3 million at the end of 2025. The company anticipates that its current cash position will be sufficient to fund operations for at least the next twelve months. Looking ahead, ADC Therapeutics plans to continue leveraging its existing cash resources, revenues from ZYNLONTA sales, and potential milestone payments from licensing agreements to support its operational needs. The company remains focused on expanding ZYNLONTA's market presence and exploring additional strategic collaborations and financing opportunities.
About ADC Therapeutics SA
ADC Therapeutics SA is a pioneering biopharmaceutical company specializing in antibody-drug conjugates (ADCs) for cancer treatment. Its flagship product, ZYNLONTA, targets CD19 for relapsed or refractory B-cell lymphomas and has received multiple regulatory approvals. The company is expanding its pipeline with innovative ADCs for solid tumors and hematologic malignancies, leveraging strategic partnerships to enhance global access and address significant unmet medical needs in oncology.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov